{"nctId":"NCT03681184","briefTitle":"A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","startDateStruct":{"date":"2018-11-27","type":"ACTUAL"},"conditions":["Primary Hyperoxaluria Type 1 (PH1)"],"count":39,"armGroups":[{"label":"Placebo/Lumasiran","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Lumasiran"]},{"label":"Lumasiran/Lumasiran","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Lumasiran"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Lumasiran","otherNames":["ALN-GO1"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing to provide written informed consent or assent and to comply with study requirements\n* Confirmation of PH1 disease\n* Meet the 24 hour urine oxalate excretion requirements\n* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days\n\nExclusion Criteria:\n\n* Clinically significant health concerns (with the exception of PH1) or clinical evidence of extrarenal systemic oxalosis\n* Clinically significant abnormal laboratory results\n* Known active or evidence of HIV or hepatitis B or C infection\n* An estimated GFR of \\< 30 mL/min/1.73m\\^2 at screening\n* Received an investigational agent within 30 days or 5 half-lives before the first dose of study drug or are in follow-up of another clinical study\n* History of kidney or liver transplant\n* Known history of multiple drug allergies or allergic reaction to an oligonucleotide or GalNAc\n* History of intolerance to subcutaneous injection\n* Women who are pregnant, planning a pregnancy, or breast-feeding or those of child bearing potential and not willing to use contraception\n* History of alcohol abuse within the last 12 months, or unable or unwilling to limit alcohol consumption throughout the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6","description":"Percent change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average percent change from baseline across Months 3 through 6. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.8","spread":"3.8"},{"groupId":"OG001","value":"-65.4","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in 24-hour Urinary Oxalate Corrected for BSA From Baseline to Month 6","description":"Absolute change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average absolute change from baseline across Months 3 through 6. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.08"},{"groupId":"OG001","value":"-1.24","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Percent Change in 24-hour Urinary Oxalate:Creatinine Ratio From Baseline to Month 6","description":"Percent change in 24-hour urinary oxalate:creatine ratio was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"5.4"},{"groupId":"OG001","value":"-62.5","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 24-hour Urinary Oxalate Level Corrected for BSA at or Below 1.5 x ULN at Month 6","description":"The upper limit of normal (ULN) = 0.514 mmol/24hr/1.73m\\^2 for 24-hour urinary oxalate excretion corrected for BSA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"84.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 24-hour Urinary Oxalate Level Corrected for BSA at or Below ULN at Month 6","description":"The upper limit of normal (ULN) = 0.514 mmol/24hr/1.73m\\^2 for 24-hour urinary oxalate excretion corrected for BSA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Plasma Oxalate From Baseline to Month 6","description":"Percent change in plasma oxalate (umol/L) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"4.3"},{"groupId":"OG001","value":"-39.8","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Plasma Oxalate From Baseline to Month 6","description":"Absolute change in plasma oxalate (umol/L) was estimated by an average percent change from baseline across Months 3 through 6. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.1"},{"groupId":"OG001","value":"-7.5","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Week 2 and Months 1, 2, 3, 4, 5 and 6","description":"eGFR is calculated from serum creatinine based on the Modification of Diet in Renal Disease formula for patients ≥18 years of age and the Schwartz Bedside Formula for patients \\>1 year to \\<18 years of age at screening. Change from baseline to Month 6 is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"9"},{"groupId":"OG001","value":"-4","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"7"},{"groupId":"OG001","value":"-2","spread":"12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"8"},{"groupId":"OG001","value":"-2","spread":"15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"6"},{"groupId":"OG001","value":"0","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":"8"},{"groupId":"OG001","value":"-4","spread":"10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":"7"},{"groupId":"OG001","value":"-6","spread":"13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"6"},{"groupId":"OG001","value":"-3","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in 24-hour Urinary Oxalate Excretion Corrected for BSA From Baseline in the Extension Period","description":"Absolute change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average absolute change from baseline in the extension periods. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.951","spread":"0.6148"},{"groupId":"OG001","value":"-1.086","spread":"0.7678"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-1.129","spread":"0.7581"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in 24-hour Urinary Oxalate Excretion Corrected by BSA From Baseline in the Extension Period","description":"Percent change in 24-hour urinary oxalate excretion corrected for BSA was estimated by an average percent change from baseline in the extension periods. Only valid urine samples without any non-protocol-related issues were included in the analysis. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.57","spread":"11.903"},{"groupId":"OG001","value":"-53.87","spread":"41.919"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-53.98","spread":"28.476"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time That 24-hour Urinary Oxalate is at or Below 1.5 × ULN During Lumasiran Treatment","description":"The upper limit of normal (ULN) = 0.514 mmol/24hr/1.73m\\^2 for 24-hour urinary oxalate excretion corrected for BSA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.44","spread":null},{"groupId":"OG001","value":"89.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in 24-hour Urinary Oxalate:Creatinine Ratio From Baseline in the Extension Period","description":"Absolute change in 24-hour urinary oxalate:creatinine ratio was estimated by an average absolute change from baseline to the end of the OLE period at Month 54 and Month 60. A negative change from Baseline indicates a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.145","spread":"0.1242"},{"groupId":"OG001","value":"-0.127","spread":"0.1063"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.138","spread":"0.1162"}]}]}]},{"type":"SECONDARY","title":"Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline in the Extension Period","description":"eGFR is calculated from serum creatinine based on the Modification of Diet in Renal Disease formula for patients ≥18 years of age and the Schwartz Bedside Formula for patients \\>1 year to \\<18 years of age at screening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.860","spread":"9.5386"},{"groupId":"OG001","value":"-6.899","spread":"12.9302"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-2.892","spread":"11.6544"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigational participant administered a medicinal product \\& which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization/prolongation of existing hospitalization, results in persistent/significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event that may not be immediately life-threatening/result in death/hospitalization but may jeopardize the participant \\& may require intervention to prevent one of the other outcomes listed above. All Lumasiran Treated Set: All participants who received any amount of lumasiran including participants who took lumasiran during 6-month double-blinded period \\& participants who initially took placebo during the 6-month double-blinded period and then switched to lumasiran during the extension period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Rate of Renal Stone Events","description":"A renal stone event is defined as a patient-reported event that includes ≥1 of the following: visit to healthcare provider because of a renal stone; medication for renal colic; stone passage; macroscopic hematuria due to a renal stone. Lower rates indicate a favorable outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"3.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null},{"groupId":"OG001","value":"1.09","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Nephrocalcinosis as Assessed by Renal Ultrasound","description":"Renal ultrasound data were used to grade medullary nephrocalcinosis findings (range: 0 to 3), where a higher grade indicates greater severity. Improving=if both sides improve, or one side improves and the other side has no change; No change=if both sides have no change; Worsening=if both sides worsen, or one side worsens and the other side has no change; Indeterminate=if one side improves and the other side worsens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Injection site reaction","Headache","Abdominal pain","COVID-19","Rhinitis"]}}}